Gain Therapeutics (GANX) Net Shares Issued and Repurchased (2021 - 2026)

Gain Therapeutics has reported Net Shares Issued and Repurchased for 6 years, with the latest figure at $798500.0 in Q1 2026.

• On a quarterly basis, Net Shares Issued and Repurchased fell 27.36% year-over-year to $798500.0 in Q1 2026; TTM through Mar 2026 was $798500.0, a 27.36% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 14.13% from the prior year.
• Net Shares Issued and Repurchased was $798500.0 for Q1 2026 at Gain Therapeutics, down from $1.2 million in the prior quarter.
• The five-year high for Net Shares Issued and Repurchased was $1.4 million in Q4 2024, with the low at $558850.0 in Q1 2023.
• Average Net Shares Issued and Repurchased over 5 years is $986081.2, with a median of $1.1 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Net Shares Issued and Repurchased declined 28.23% in 2023, then soared 96.39% in 2024.
• Over 5 years, Net Shares Issued and Repurchased stood at $1.0 million in 2022, then decreased by 28.23% to $721850.0 in 2023, then jumped by 94.29% to $1.4 million in 2024, then declined by 14.13% to $1.2 million in 2025, then plunged by 33.7% to $798500.0 in 2026.
• The last three Net Shares Issued and Repurchased figures came in at $798500.0 (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q1 2025), per Business Quant data.